BE2010C011I2 - - Google Patents

Info

Publication number
BE2010C011I2
BE2010C011I2 BE2010C011C BE2010C011C BE2010C011I2 BE 2010C011 I2 BE2010C011 I2 BE 2010C011I2 BE 2010C011 C BE2010C011 C BE 2010C011C BE 2010C011 C BE2010C011 C BE 2010C011C BE 2010C011 I2 BE2010C011 I2 BE 2010C011I2
Authority
BE
Belgium
Application number
BE2010C011C
Other languages
French (fr)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10854788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2010C011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BE2010C011I2 publication Critical patent/BE2010C011I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/80—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2010C011C 1999-06-04 2010-02-24 BE2010C011I2 (pm)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9913083.3A GB9913083D0 (en) 1999-06-04 1999-06-04 Organic compounds

Publications (1)

Publication Number Publication Date
BE2010C011I2 true BE2010C011I2 (pm) 2019-05-21

Family

ID=10854788

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2010C011C BE2010C011I2 (pm) 1999-06-04 2010-02-24

Country Status (38)

Country Link
US (9) US6878721B1 (pm)
EP (2) EP1183240B1 (pm)
JP (1) JP3785365B2 (pm)
KR (1) KR100718615B1 (pm)
CN (1) CN1156451C (pm)
AR (1) AR035548A1 (pm)
AT (1) ATE440083T1 (pm)
AU (1) AU765919B2 (pm)
BE (1) BE2010C011I2 (pm)
BR (1) BRPI0011324B8 (pm)
CA (1) CA2375810C (pm)
CO (1) CO5170518A1 (pm)
CY (3) CY1109604T1 (pm)
CZ (1) CZ302403B6 (pm)
DE (2) DE60042781D1 (pm)
DK (2) DK2332915T3 (pm)
ES (2) ES2402535T3 (pm)
FR (1) FR10C0006I2 (pm)
GB (1) GB9913083D0 (pm)
HK (1) HK1045837B (pm)
HU (1) HU227034B1 (pm)
IL (2) IL146578A0 (pm)
LU (1) LU91651I2 (pm)
MX (1) MXPA01012474A (pm)
MY (1) MY126951A (pm)
NL (1) NL300437I1 (pm)
NO (2) NO322944B1 (pm)
NZ (1) NZ515669A (pm)
PE (1) PE20010219A1 (pm)
PL (1) PL198847B1 (pm)
PT (2) PT1183240E (pm)
RU (1) RU2244709C2 (pm)
SI (1) SI1183240T1 (pm)
SK (1) SK287260B6 (pm)
TR (1) TR200103497T2 (pm)
TW (1) TWI253447B (pm)
WO (1) WO2000075114A1 (pm)
ZA (1) ZA200109931B (pm)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
GB0121214D0 (en) * 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
EP2311818B1 (en) 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
US6933410B2 (en) 2002-03-08 2005-08-23 Novartis Ag Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine
DE10256080A1 (de) * 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropiumhaltige Arzneimittelkombination für die Inhalation
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20100399A1 (es) * 2003-04-02 2010-06-01 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
US7745462B2 (en) 2003-04-04 2010-06-29 Novartis Ag Quinoline-2-one derivatives for the treatment of airways diseases
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
BRPI0413129A (pt) * 2003-07-29 2006-10-03 Boehringer Ingelheim Int medicamentos para inalação compreendendo betamiméticos e anticolinérgico
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005092861A1 (en) * 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1574501A1 (en) * 2004-03-11 2005-09-14 Pfizer Limited Quinolinone derivatives, pharmaceutical compositions containing them and their use
WO2005089718A2 (en) * 2004-03-23 2005-09-29 Novartis Ag Pharmaceutical compositions
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
WO2006031556A2 (en) * 2004-09-10 2006-03-23 Theravance. Inc. Amidine substituted aryl aniline compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
US20090298875A1 (en) * 2005-08-26 2009-12-03 Astrazeneca Ab A Combination of Compounds, Which Can be Used in the Treatment of Respiratory Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
TWI392493B (zh) * 2005-10-26 2013-04-11 Novartis Ag 格隆溴銨(GLYCOPYRROLATE)及β2腎上腺素受體激動劑之組合
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
MX2008013431A (es) 2006-04-21 2008-11-04 Novartis Ag Derivados de purina para utilizarse como agonistas del receptor de adenosina a2a.
WO2008000839A1 (en) * 2006-06-30 2008-01-03 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
EP1878722A1 (en) * 2006-07-13 2008-01-16 Novartis AG Quinolinone derivatives and their pharmaceutical compositions
EP1914227A1 (en) * 2006-08-31 2008-04-23 Novartis AG Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
RS51644B (en) 2007-01-10 2011-10-31 Irm Llc. UNITS AND PREPARATIONS AS CHANNEL INHIBITORS ACTIVATING PROSTHESES
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
WO2008097673A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2155721B1 (en) 2007-05-07 2011-02-23 Novartis AG Organic compounds
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
CA2711637A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
ES2535736T3 (es) 2008-06-10 2015-05-14 Novartis Ag Derivados de pirazina como bloqueadores de los canales de sodio epitelial
MX2010013477A (es) 2008-06-18 2010-12-21 Astrazeneca Ab Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta2 para el tratamiento de trastornos respiratorios.
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010076553A1 (en) 2008-12-30 2010-07-08 Dr. Reddy's Laboratories Ltd Sulfonamide compounds for the treatment of respiratory disorders
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
TW201040154A (en) * 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted indanes, process for preparation thereof and use thereof as a medicament
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
SG10201404886PA (en) 2009-08-17 2014-10-30 Intellikine Llc Heterocyclic compounds and uses thereof
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011056929A1 (en) 2009-11-04 2011-05-12 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
KR20130002316A (ko) * 2010-02-18 2013-01-07 아스트라제네카 아베 시클로프로필 벤즈아미드 유도체의 신규 결정질 형태
US8680303B2 (en) 2010-03-01 2014-03-25 Massachusetts Institute Of Technology Epoxidation catalysts
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
CA2804744C (en) 2010-07-14 2019-05-28 Novartis Ag Ip receptor agonist 1,8-naphthyridinyl and 7,8-dihydropyrido[3,2-b]pyrazinyl heterocyclic compounds
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
CN107998109A (zh) 2010-10-12 2018-05-08 西普拉有限公司 药物组合物
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
ES2551592T3 (es) 2011-02-25 2015-11-20 Novartis Ag Pirazolo[1,5-a]piridinas como inhibidores de TRK
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP5886433B2 (ja) 2011-09-16 2016-03-16 ノバルティス アーゲー 嚢胞性線維症処置のためのヘテロ環式化合物
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105057A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
JP6058698B2 (ja) 2012-01-13 2017-01-11 ノバルティス アーゲー Ｉｐ受容体アゴニストの塩
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
WO2014008639A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 制备茚达特罗的方法
WO2014008640A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
CN103539677B (zh) * 2012-07-16 2015-04-22 武汉万知生物医药有限公司 一种5,6-二乙基-2,3-二氢-1h-茚-2-胺盐酸盐的制备方法
EP2897937B1 (en) 2012-09-21 2017-12-06 Crystal Pharma S.A.U Process for the preparation of indacaterol and intermediates thereof
WO2014044288A1 (en) 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
SG11201504633PA (en) 2012-12-19 2015-07-30 Novartis Ag Autotaxin inhibitors
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
ES2637719T3 (es) 2013-02-13 2017-10-16 Novartis Ag Compuestos heterocíclicos agonistas del receptor IP
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
MX2015012529A (es) 2013-03-14 2016-07-05 Novartis Ag Deamorfizacion de formulaciones secadas por pulverizacion a traves de pulverizacion de la mezcla.
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
CZ306252B6 (cs) * 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
EP2978745B1 (en) * 2013-03-27 2017-03-15 Laboratorios Lesvi, S.L. Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one
US20160168119A1 (en) 2013-07-18 2016-06-16 Novartis Ag Autotaxin inhibitors
JP6424219B2 (ja) 2013-07-18 2018-11-14 ノバルティス アーゲー 複素芳香環−ベンジル−アミド−サイクルコアを含むオートタキシン阻害剤
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CN104744360B (zh) * 2013-12-26 2017-02-22 成都伊诺达博医药科技有限公司 一种合成茚达特罗的新方法
PT3092217T (pt) 2014-01-09 2020-09-04 Ramamohan Rao Davuluri Processo inovador para preparação de indacaterol ou dos seus sais farmaceuticamente aceitáveis
CN103830193A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗片制剂及其制备方法
CN103830195A (zh) * 2014-03-11 2014-06-04 熊妲妮 一种茚达特罗片及其制备方法
RU2016141948A (ru) 2014-03-27 2018-04-27 Новартис Аг Высушенные распылением дисперсии твердое-в-масле-в-воде активных фармацевтических ингредиентов для ингаляции
WO2015162558A1 (en) 2014-04-24 2015-10-29 Novartis Ag Autotaxin inhibitors
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
KR20160141855A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피라진 유도체
EA033571B1 (ru) 2014-04-24 2019-11-06 Novartis Ag Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
DE102014217201A1 (de) 2014-08-28 2016-03-03 Henkel Ag & Co. Kgaa Verwendung einer Kombination von Rheolate FX 1100 und Luviskol K90
DE102014217205A1 (de) 2014-08-28 2016-03-03 Henkel Ag & Co. Kgaa Verwendung einer Kombination von Rheolate FX 1100 und Luviskol VA 64 W
CN107111687A (zh) 2015-01-20 2017-08-29 诺华股份有限公司 使用连接的物理设备以及其间的数据传输进行应用解锁
CN107735390B (zh) 2015-01-20 2021-06-08 欧伦股份公司 茚满胺衍生物的制备方法和新合成中间体
CN107531636B (zh) * 2015-04-09 2022-11-25 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
EP3111978B1 (en) 2015-07-03 2021-09-01 Novartis AG Inhaler adapted to read information stored in a data storage means of a container
ITUB20153978A1 (it) * 2015-09-28 2017-03-28 Laboratorio Chimico Int S P A Procedimento per la preparazione di derivati di indanammina e di nuovi intermedi di sintesi.
CN105884626B (zh) * 2016-05-04 2017-10-20 龙曦宁（上海）医药科技有限公司 一种2‑氨基茚满衍生物的合成方法及其产品
CN108101841B (zh) * 2016-11-24 2021-04-06 江苏恒瑞医药股份有限公司 一种制备茚达特罗或其盐的方法
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
WO2019135101A1 (en) 2018-01-02 2019-07-11 Deva Holding Anonim Sirketi A process for preparation of 5-(2-(substituted-amino)-1-hydroxyethyl)-8-(substituted-oxy) quinolin-2(1h)-one
EP3768765B1 (en) 2018-03-19 2023-05-17 Dow Silicones Corporation Polyolefin-polydiorganosiloxane block copolymer and hydrosilylaton reaction method for the synthesis thereof
JP2021518460A (ja) 2018-03-19 2021-08-02 ダウ シリコーンズ コーポレーション ポリオレフィン−ポリジオルガノシロキサンコポリマーを含有するホットメルト接着剤組成物ならびにその調製方法および使用方法
EP3768793B1 (en) 2018-03-19 2023-09-27 Dow Silicones Corporation Polyorganosiloxane hot melt adhesive compositions containing polyolefin - polydiorganoosiloxane copolymers and methods for the preparation and use thereof
WO2019182720A1 (en) 2018-03-19 2019-09-26 Dow Silicones Corporation Polyolefin-polydiorganosiioxane block copolymer and method for the synthesis thereof
US11702512B2 (en) 2018-07-17 2023-07-18 Dow Silicones Corporation Polysiloxane resin-polyolefin copolymer and methods for the preparation and use thereof
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
EP3860712A1 (en) 2018-10-05 2021-08-11 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CN109369417B (zh) * 2018-10-19 2021-07-06 诚达药业股份有限公司 一种2-氨基茚满衍生物的制备方法
WO2020105012A1 (en) 2018-11-22 2020-05-28 Glenmark Specialty S.A. Sterile compositions of indacaterol suitable for nebulization
US20200215051A1 (en) 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
CN109896967B (zh) * 2019-04-04 2021-10-22 上海工程技术大学 一种间二乙氨基苯酚的制备方法
CN109896966B (zh) * 2019-04-04 2021-10-22 上海工程技术大学 一种n,n-二丁基间氨基苯酚的制备方法
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
CN110229078A (zh) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 一种茚达特罗起始原料开环杂质的制备
US20200383960A1 (en) 2019-06-10 2020-12-10 Novartis Ag Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
CN114341132A (zh) 2019-08-28 2022-04-12 诺华股份有限公司 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US20230159504A1 (en) * 2020-04-03 2023-05-25 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)
PE20230855A1 (es) 2020-08-14 2023-05-29 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos
EP4221707A4 (en) 2020-09-29 2024-08-28 Aerorx Therapeutics LLC Liquid formulations of indacaterol
CN115677577B (zh) * 2021-11-03 2024-11-15 中国药科大学 靶向srsf6蛋白的小分子化合物及其制备方法和用途
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
CN115521254B (zh) * 2022-09-27 2024-05-31 中国药科大学 一种茚达特罗衍生物及其制备方法和应用
WO2024153813A1 (en) 2023-01-20 2024-07-25 Atrogi Ab Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
WO2024206662A1 (en) * 2023-03-30 2024-10-03 Aerorx Therapeutics Llc Liquid formulations of indacaterol and glycopyrronium
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2354959C3 (de) * 1973-11-02 1980-02-07 Dr. Karl Thomae Gmbh, 7950 Biberach Neues Verfahren zur Herstellung von 4-Amino-3,5 dihalogen phenyl-athanolaminen
GB8707123D0 (en) 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
ZA903906B (en) * 1989-05-25 1992-02-26 Takeda Chemical Industries Ltd Benzocycloalkane derivatives and production thereof
AU632809B2 (en) 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
WO1992018641A1 (en) * 1991-04-10 1992-10-29 The Trustees Of Boston University Interleukin-8 receptors and related molecules and methods
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
JPH0518007A (ja) 1991-07-05 1993-01-26 Konoike Constr Ltd 鉄骨梁との接合部を内蔵したｐｃ柱
IL104567A (en) * 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO1993018007A1 (fr) * 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
ES2115003T3 (es) 1993-01-29 1998-06-16 American Cyanamid Co Aminocicloalcanobenzodioxoles como agentes adrenergicos selectivos beta-3.
ES2139750T3 (es) * 1993-08-06 2000-02-16 Upjohn Co 2-aminoindanos como ligandos selectivos d3 de la dopamina.
FR2711407B1 (fr) * 1993-10-19 1996-01-26 Allevard Sa Perfectionnements aux barres de torsion métalliques.
US5578638A (en) 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
NZ301492A (en) 1995-02-01 1999-01-28 Upjohn Co Substituted 2-aminoindane derivatives and medicaments
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
SG72727A1 (en) * 1996-02-19 2000-05-23 Kissei Pharmaceutical 3,4-Disubstituted phenylethanolaminotetralincarboxamide derivatives
JP3708624B2 (ja) 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
JP3690071B2 (ja) 1997-06-24 2005-08-31 井関農機株式会社 ロータリ耕耘具の防護装置
WO1999009001A1 (fr) 1997-08-19 1999-02-25 Kissei Pharmaceutical Co., Ltd. Derives de phenylethanolaminotetraline et bronchodilatateurs
JP2002512639A (ja) * 1998-04-06 2002-04-23 藤沢薬品工業株式会社 プロパノールアミン誘導体
AU6610001A (en) 2000-06-27 2002-01-08 S A L V A T Lab Sa Carbamates derived from arylalkylamines

Also Published As

Publication number Publication date
HU227034B1 (en) 2010-05-28
US7622483B2 (en) 2009-11-24
PE20010219A1 (es) 2001-03-21
IL146578A0 (en) 2002-07-25
PL198847B1 (pl) 2008-07-31
NO20015912L (no) 2002-01-21
SI1183240T1 (sl) 2010-01-29
FR10C0006I1 (pm) 2010-03-26
US20120077838A1 (en) 2012-03-29
DE122010000009I1 (de) 2010-07-01
US20120302531A1 (en) 2012-11-29
ES2331457T3 (es) 2010-01-05
MY126951A (en) 2006-11-30
JP2003501417A (ja) 2003-01-14
LU91651I9 (pm) 2019-01-03
US7820694B2 (en) 2010-10-26
US20110034509A1 (en) 2011-02-10
FR10C0006I2 (fr) 2011-04-01
NL300437I1 (nl) 2010-04-01
CY2010003I2 (el) 2012-01-25
AU5074500A (en) 2000-12-28
PT1183240E (pt) 2009-11-03
DE60042781D1 (de) 2009-10-01
NO20015912D0 (no) 2001-12-03
KR100718615B1 (ko) 2007-05-16
KR20020012590A (ko) 2002-02-16
BR0011324B1 (pt) 2014-11-25
AR035548A1 (es) 2004-06-16
HK1154584A1 (en) 2012-04-27
CY1114120T1 (el) 2016-07-27
SK17432001A3 (sk) 2002-06-04
TR200103497T2 (tr) 2002-05-21
HK1045837A1 (en) 2002-12-13
US6878721B1 (en) 2005-04-12
CZ302403B6 (cs) 2011-05-04
MXPA01012474A (es) 2002-06-04
ZA200109931B (en) 2002-06-05
TWI253447B (en) 2006-04-21
EP2332915B1 (en) 2013-02-27
US8436017B2 (en) 2013-05-07
EP2332915A1 (en) 2011-06-15
US8283362B2 (en) 2012-10-09
DE122010000009I2 (de) 2012-08-09
IL146578A (en) 2007-05-15
NO2010014I1 (no) 2010-07-26
NO2010014I2 (pm) 2011-10-17
AU765919B2 (en) 2003-10-02
CA2375810A1 (en) 2000-12-14
ES2402535T3 (es) 2013-05-06
US9040559B2 (en) 2015-05-26
NO322944B1 (no) 2006-12-18
HUP0201658A2 (en) 2002-08-28
GB9913083D0 (en) 1999-08-04
CY1109604T1 (el) 2012-01-25
RU2244709C2 (ru) 2005-01-20
US20140343091A1 (en) 2014-11-20
CY2010003I1 (el) 2012-01-25
US8796307B2 (en) 2014-08-05
CO5170518A1 (es) 2002-06-27
WO2000075114A1 (en) 2000-12-14
US8067437B2 (en) 2011-11-29
EP1183240A1 (en) 2002-03-06
HUP0201658A3 (en) 2005-01-28
BRPI0011324B8 (pt) 2021-05-25
SK287260B6 (sk) 2010-04-07
JP3785365B2 (ja) 2006-06-14
EP1183240B1 (en) 2009-08-19
CZ20014301A3 (cs) 2002-03-13
DK2332915T3 (da) 2013-05-27
CN1353692A (zh) 2002-06-12
ATE440083T1 (de) 2009-09-15
US20140066478A1 (en) 2014-03-06
US20130231367A1 (en) 2013-09-05
LU91651I2 (fr) 2010-04-19
PL352100A1 (en) 2003-07-28
BR0011324A (pt) 2002-03-05
DK1183240T3 (da) 2009-11-23
US20100029705A1 (en) 2010-02-04
US8658673B2 (en) 2014-02-25
HK1045837B (en) 2010-03-26
CN1156451C (zh) 2004-07-07
PT2332915E (pt) 2013-04-11
CA2375810C (en) 2010-09-07
US20050153957A1 (en) 2005-07-14
NZ515669A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
BE2018C020I2 (pm)
BE2016C007I2 (pm)
BE2015C057I2 (pm)
BE2015C018I2 (pm)
BE2014C017I2 (pm)
JP2002529136A5 (pm)
FR10C0006I1 (pm)
BRPI0017527B8 (pm)
JP2002519716A5 (pm)
BRPI0001672A2 (pm)
JP2002531762A5 (pm)
BRPI0001542A2 (pm)
JP2002532277A5 (pm)
BRPI0012675B8 (pm)
JP2002522247A5 (pm)
BRPI0017522A2 (pm)
JP2002523877A5 (pm)
BRMU7902607U2 (pm)
BRPI9917761A2 (pm)
IN191334B (pm)
ECSMU990150U (pm)
FR2766168A3 (pm)
IN188473B (pm)
IN191487B (pm)
FR2775174A3 (pm)